LARIMAR THERAPEUTICS, INC. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
LARIMAR THERAPEUTICS, INC. (LRMR) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $0 as of 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2017-11-07
- 2017-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2015-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2015-06-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2015-03-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-13 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-14 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |